On Friday, Pfizer Inc (NYSE:PFE) revealed its drug for an advanced form of lung cancer showed promising long-term results in a late-stage trial. On Monday, Moderna (NASDAQ:MRNA) and Merck & Co (NYSE:MRK) also reported durable efficiency of their combined melanoma treatment that consists of an experimental mRNA vaccine and Merck's blockbuster immunotherapy, Keytruda.

Pfizer Is Aiming To Set The Treatment Standard For Lung Cancer

With encouraging results, Pfizer is getting another step closer to establish its drug as the new standard treatment for lung cancer. Lorbrena has helped patients live longer without their cancer progressing...